Completeness of response and quality of life in mood and anxiety disorders
- PMID: 11098422
- DOI: 10.1002/1520-6394(2000)12:1+<95::AID-DA14>3.0.CO;2-U
Completeness of response and quality of life in mood and anxiety disorders
Abstract
Mental health care has traditionally focused on the need to document relief of specific symptoms of a psychiatric disorder, as well as how the patient functions in social roles. Recently, there has been increased attention paid to the issue of quality of life (QOL) and psychiatric illness. There has been a growing recognition that different treatment options may vary in their effects on the patient's ability to function in multiple life domains. Studies focusing on the QOL in patients suffering from mood and anxiety disorders have become more prevalent. Depression and anxiety disorders impose a substantial cost on society in terms of both psychiatric service costs as well as the loss of the individual to society through lost work production. However, a change in the severity of depression or anxiety often correlates with a change in disability and health service utilization. Lately, there have been a number of treatment studies of anxiety and depressive disorders that have examined the effect of treatment on QOL. Although treatment may reduce the severity and frequency of target symptoms, the patient's assessment of QOL helps to differentiate a true treatment response and remission from a partial response. The evaluation of what constitutes an adequate treatment response or remission is complicated and likely requires multiple assessment instruments in order to develop a complete understanding. In both anxiety and depressive disorders, the patient suffers from impaired functioning, which results in increased healthcare utilization. Because these patients do respond to treatment, the idea of "wellness" as a high end state treatment outcome should be an important consideration when selecting a treatment option.
Similar articles
-
Cost-outcome of anxiety treatment intervention in primary care in Hungary.J Ment Health Policy Econ. 2002 Sep;5(3):115-20. J Ment Health Policy Econ. 2002. PMID: 12728198
-
Quality of life in the anxiety disorders.Harv Rev Psychiatry. 2000 Dec;8(6):273-82. Harv Rev Psychiatry. 2000. PMID: 11133822 Review.
-
Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: a cross-sectional study in a community hospital outpatient centre.Eur J Cancer Care (Engl). 2007 Mar;16(2):130-6. doi: 10.1111/j.1365-2354.2006.00720.x. Eur J Cancer Care (Engl). 2007. PMID: 17371421 Review.
-
[Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].Encephale. 2003 Sep-Oct;29(5):438-44. Encephale. 2003. PMID: 14615693 French.
-
Barriers to help-seeking, detection, and adequate treatment for anxiety and mood disorders: implications for health care policy.J Clin Psychiatry. 2007;68 Suppl 2:20-6. J Clin Psychiatry. 2007. PMID: 17288503
Cited by
-
Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.Drug Saf. 2011 Aug 1;34(8):623-39. doi: 10.2165/11592070-000000000-00000. Drug Saf. 2011. PMID: 21751824 Review.
-
Disability and quality of life in post-traumatic stress disorder: impact of drug treatment.Pharmacoeconomics. 2006;24(10):989-98. doi: 10.2165/00019053-200624100-00006. Pharmacoeconomics. 2006. PMID: 17002481 Review.
-
Relationship Between Psychological Distress and Poverty Among Japanese Workers During the COVID-19 Pandemic: A Prospective Cohort Study.J Occup Environ Med. 2023 Feb 1;65(2):e83-e87. doi: 10.1097/JOM.0000000000002760. Epub 2022 Nov 23. J Occup Environ Med. 2023. PMID: 36418234 Free PMC article.
-
Neuropsychiatric complications of aging with HIV.J Neurovirol. 2012 Aug;18(4):277-90. doi: 10.1007/s13365-012-0108-z. Epub 2012 May 30. J Neurovirol. 2012. PMID: 22644745 Free PMC article. Review.
-
The Identification of Potential Anti-Depression/Anxiety Drug Targets by Stress-Induced Rat Brain Regional Proteome and Network Analyses.Neurochem Res. 2024 Oct;49(10):2957-2971. doi: 10.1007/s11064-024-04220-x. Epub 2024 Aug 1. Neurochem Res. 2024. PMID: 39088164
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical